Prelim. Results from Phase III Trial on AMAG Pharma's (AMAG) Feraheme Met Primary Endpoints
Go back to Prelim. Results from Phase III Trial on AMAG Pharma's (AMAG) Feraheme Met Primary Endpoints| AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) | Delayed: 13.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.75 | 52 Week High | $31.85 | |||
| Open | $2.69 | 52 Week Low | $17.92 | |||
| Day High | $13.75 | P/E | N/A | |||
| Day Low | $13.75 | EPS | $-0.44 | |||
| Volume | 16,717 | |||||
